Amicus Therapeutics, Inc. (NASDAQ:FOLD) said its lead drug to treat fat-storage disorder was found effective in patients after 12 months of treatment in a late-stage trial. The company’s shares jumped about 33 percent in premarket trading. They closed at $1.84 on the Nasdaq on Monday. Amicus Therapeutics, Inc. (NASDAQ:FOLD) stock opened today at $2.33 and is currently trading at $2.39. The stock showed a negative weekly performance of -0.54%.
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of OmniAmerican Bancorp, Inc. (NASDAQ:OABC) relating to the sale of the Company to Southside Bancshares, Inc. (NASDAQ: SBSI). On April 29, 2014, the two companies announced the signing of a definitive merger agreement pursuant to which Southside will acquire OmniAmerican in a merger valued at roughly $307 million in the aggregate. As a result of the merger, OmniAmerican shareholders are only anticipated to receive 0.4459 shares of Southside common stock and $13.125 per share in cash in exchange for each share of OmniAmerican stock they own (roughly $26.71 per share total consideration).OmniAmerican Bancorp, Inc. (NASDAQ:OABC) stock opened at $25.63, in current trading session and currently is at $25.31, by gaining 10.38%.The 52 week range of $20.46-$25.73. Company’s market capitalization is $292.37 million.
Central European Media Enterprises Ltd. (NASDAQ:CETV) could find itself under new ownership, with two Czech entrepreneurs – Petr Kellner and Pavel Tykac – in pole position to take a majority stake in the company. E15 reports that representatives of Kellner and Tykac have met with Time Warner, currently the majority shareholder in CME, on several occasions in London but have yet to finalise an agreement. Central European Media Enterprises Ltd. (NASDAQ:CETV) stock is currently trading at $2.73.The EPS of the stock is -2.22. Company’s market capitalization is $368.11 million.
XOMA Corp (NASDAQ:XOMA) was upgraded by analysts at MLV & Co from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday. The firm currently has a $7.00 price target on the stock. MLV & Co’s price target would suggest a potential upside of 83.25% from the company’s current price. The analysts noted that the move was a valuation call.XOMA Corp (NASDAQ:XOMA) stock opened the session at $4.11, and now is at $4.37. The 52 week range of the XOMA stock remained $3.02-$9.57 and the day range was $4.02-$4.38.